Stryker stock holds gains as medical device growth supports valuation

Stryker stock is trading near the upper band of its recent 52?week range as the medical technology group Stryker Corp. (US8636671013) continues to post growing revenue and earnings from its global orthopedic implant and surgical equipment portfolio. As of mid July 2026, the company remains one of the larger constituents in major US healthcare indices, reflecting its scale in medical devices and hospital capital equipment.

Revenue above 20 billion dollars

According to the companys latest published annual figures for fiscal 2024, Stryker reported full?year net sales of roughly $22.3 billion, marking an increase of about $2.0 billion from the approximately $20.3 billion generated in fiscal 2023. The double?digit dollar increase underlines how procedure volumes and equipment demand have recovered compared with earlier years impacted by hospital disruptions.

Management also highlighted that organic sales growth in fiscal 2024 was in the high single?digit to low double?digit range compared with 2023, reflecting contributions from both price and volume. Within that total, orthopedic and spine implants, together with surgical technologies and neurotechnology, accounted for a substantial portion of the $22.3 billion revenue base in 2024, underlining the breadth of the companys hospital customer relationships.

Earnings and margin development

Alongside higher revenue, Stryker reported that diluted earnings per share on a GAAP basis for fiscal 2024 increased compared with 2023, aided by operating leverage as sales volumes expanded. On an adjusted basis, the companys diluted EPS for 2024 was several tens of cents per share higher than the level reported for 2023, supported by cost control and mix effects from faster?growing franchises.

The companys operating margin for 2024 also improved versus 2023, with the margin expansion translating part of the roughly $2.0 billion revenue increase into higher profit rather than pure cost growth. For investors, the margin trajectory is important because Stryker continues to spend significantly on research and development and on sales and service capabilities to protect its position in hospitals and ambulatory surgery centers.

Mako robotic system in focus

One of Strykers flagship technologies is the Mako robotic?arm assisted surgery platform, which is used by orthopedic surgeons to plan and execute knee and hip replacement procedures with the aim of improving precision and consistency. The installed base of Mako systems has grown steadily over recent years as more hospitals and surgical centers adopt robotic technologies for joint replacement.

In recent reporting periods, the company has indicated that growth in revenue from robotic systems, associated implants, and service contracts has been faster than the overall group average. Each new Mako robot sale not only brings in capital equipment revenue but also typically supports recurring implant and service revenue over a multi?year period, increasing the attractiveness of the franchise from a long?term cash flow perspective.

Stryker stock and market positioning

Stryker stock is listed on the New York Stock Exchange and is included in major US equity indices that track large healthcare and medical device companies. The market capitalization has been above the $100 billion threshold for parts of 2024 and 2025, underlining how investors value the companys scale and diversified medical technology portfolio.

Compared with historical levels, the share price has traded in the upper portion of its 52?week corridor, reflecting the combination of revenue growth from $20.3 billion in 2023 to about $22.3 billion in 2024 and the improvement in margins over the same time frame. For investors, key variables now include whether procedure volumes in orthopedics remain strong and how quickly newer technologies such as robotic surgery continue to be adopted.